Table 1 The correlation of USP22 immunostaining with the clinical features of NSCLC patients
Variable* |  | Negative N (%) | 1 +  N (%) | 2 +  N (%) | 3 +  N (%) | P-value |
|---|---|---|---|---|---|---|
Age Group | <= 60 year | 11 (17) | 3 (10) | 12 (21) | 11 (25) | 0.4045 |
>  60 year | 54 (83) | 27 (90) | 46 (79) | 33 (75) |  | |
Sex | Male | 32 (49) | 17 (56) | 27 (47) | 24 (56) | 0.7232 |
Female | 33 (51) | 13 (44) | 31 (53) | 19 (44) | Â | |
Tobacco History | Never used | 8 (14) | 9 (32) | 6 (13) | 3 (9) | 0.0445 |
Previous use | 34 (58) | 16 (57) | 31 (65) | 17 (50) | Â | |
Current use | 17 (29) | 3 (11) | 11 (23) | 14 (41) | Â | |
Histology | Adenocarcinoma | 40 (62) | 18 (60) | 34 (59) | 24 (56) | 0.9469 |
SCC | 25 (38) | 12 (40) | 24 (41) | 19 (44) | Â | |
Grade | Well Differentiated | 5 (8) | 4 (14) | 9 (16) | 8 (19) | 0.5089 |
Moderately Differentiated | 28 (44) | 15 (53) | 27 (48) | 16 (38) | Â | |
Poorly Differentiated | 30 (48) | 9 (33) | 20 (36) | 18 (45) | Â | |
Path Stage | I | 39 (61) | 17 (56) | 33 (59) | 34 (79) | 0.0883 |
II | 16 (25) | 7 (24) | 8 (14) | 3 (7) | Â | |
III | 9 (14) | 6 (20) | 15 (27) | 6 (14) | Â | |
Recurrence | No | 51 (80) | 26 (87) | 51 (91) | 30 (70) | 0.0439 |
Yes | 13 (20) | 4 (13) | 5 (9) | 13 (30) | Â |